BioGaia Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Theresa Agnew

Chief executive officer

kr6.8m

Total compensation

CEO salary percentage	19.4%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	3yrs
Board average tenure	3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Theresa Agnew's remuneration changed compared to BioGaia's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr7m	kr1m	kr365m

Compensation vs Market: Theresa's total compensation ($USD613.73K) is below average for companies of similar size in the UK market ($USD1.33M).

Compensation vs Earnings: Insufficient data to compare Theresa's compensation with company performance.

CEO

Theresa Agnew (57 yo)

less than a year

Tenure

kr6,750,250

Compensation

Ms. Theresa P. Agnew serves as President of BioGaia AB (publ) since September 2023 and serves as its Chief Executive Officer since 25 September 2023. She is a global business leader with consumer healthcar...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter Rothschild	Founder & Chairman	6.1yrs	kr1.33m	no data
Theresa Agnew	CEO & President	less than a year	kr6.75m	no data
Alexander Kotsinas	Executive VP & CFO	4.5yrs	kr3.07m	0.0030% SEK 353.6k
Ludvig Milesson	Chief Operating Officer	1.1yrs	no data	0.0012% SEK 147.6k
Gianfranco Grompone	Chief Scientific Officer and VP of Research & Development	4.3yrs	no data	no data
Caroline Mofors	Chief Legal Officer	1.3yrs	no data	no data
Linda Hagglund	Vice President of Marketing	3yrs	no data	0.00019% SEK 22.6k
Angelika Kjelldorff	Chief HR Officer	5.3yrs	no data	0.00050% SEK 59.5k
Sebastian Heimfors	VP & Chief Commercial Officer	2.2yrs	no data	no data
Jonathan Gromark	Sustainability Manager	no data	no data	no data
Keitaro Nomura	MD & President of BioGaia Japan Inc.	no data	no data	no data

3.0yrs

Average Tenure

51yo

Average Age

Experienced Management: 0GTN's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Peter Rothschild	Founder & Chairman	6.1yrs	kr1.33m	no data
David E. Dangoor	Independent Deputy Board Chairman	21.3yrs	kr590.00k	1.73% SEK 206.3m
Vesa Koskinen	Director	less than a year	kr275.00k	no data
Barbro Friden	Director	less than a year	kr275.00k	0.00050% SEK 59.5k
Anthon Jahreskog	Independent Director	9yrs	kr405.00k	0.0029% SEK 340.5k
Vanessa Rothschild	Director	4yrs	kr275.00k	0.00016% SEK 19.0k
Benedicte Flambard	Director	2yrs	kr275.00k	no data
Outi Armstrong	Director	less than a year	kr275.00k	no data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Board: 0GTN's board of directors are considered experienced (3 years average tenure).

BioGaia Management

Management criteria checks 3/4

Key information

Recent management updates

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Less than half of directors are independent

Independent Director recently bought kr51k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Recent updates

Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)

Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)

Biogaia AB (Publ) Proposes an Extra Dividend

BioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024

Third quarter 2023 earnings released

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Second quarter 2023 earnings released

BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults

Less than half of directors are independent

First quarter 2023 earnings released

BioGaia AB (Publ) Approves Dividend for 2022

Upcoming dividend of kr2.90 per share at 2.8% yield

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

Independent Director recently bought kr51k worth of stock

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

BioGaia AB (publ) Proposes Ordinary Dividend

Third quarter 2022 earnings released

Investor sentiment improved over the past week

BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021)

Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

BioGaia AB (publ) Approves Extra Dividend

First quarter 2022 earnings released

Upcoming dividend of kr14.92 per share

BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022

BioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022

Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biogaia AB (Publ) Proposes Ordinary Dividend

BioGaia's Probiotic Reduces Inflammation in Patients with Diverticulitis

BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1)

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020)

BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million.

Vice President of RA & Legal recently bought kr103k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Biogaia AB (Publ) Approves Dividend

First quarter 2021 earnings released

Upcoming dividend of kr3.41 per share

Full year 2020 earnings released: EPS kr10.07

New 90-day low: kr419

CEO & President recently bought kr99k worth of stock

Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019)

Revenue beats expectations

New 90-day low: kr444

BioGaia AB (publ) Elects Niklas Ringby as New Board Member

Market bids up stock over the past week

BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion.

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Market pulls back on stock over the past week

New 90-day low: kr473

Biogaia Announces L. reuteri Protectis Reduces Pain in Children with Functional Abdominal Pain

New 90-day high - kr582

BioGaia AB (publ) to Report First Half, 2021 Results on Aug 12, 2021